Home › Blog › Weight Loss › Weight Loss Injections UK 2026

Weight Loss Injections UK 2026: Everything You Need to Know

Overview: Weight Loss Injections in the UK in 2026

Weight loss injections have transformed the clinical management of obesity in the UK. Over 2 million people were paying privately for GLP-1 weight loss medications by July 2025, according to IQVIA prescription data — a figure that represents a fundamental shift in how obesity is treated in this country. The clinical evidence behind the latest medications is extraordinary: average weight loss of more than 20% of starting body weight in controlled trials, with some patients achieving results previously only associated with bariatric surgery.

But with that growth has come significant complexity. Dozens of providers now offer online prescriptions. Prices vary enormously. Quality of clinical oversight ranges from rigorous to dangerously inadequate. Counterfeit weight loss injections — seized in record numbers by the MHRA in 2025 — are a genuine and growing patient safety risk. And for patients navigating this market without clinical guidance, making the right decision has never been more difficult.

I am Shadeia Younis, the founder and superintendent pharmacist at Slinic. I have 25 years of clinical pharmacy experience and I have built Slinic as a GPhC-regulated, NHS-contracted pharmacy that puts clinical standards above commercial pressures. This guide gives you the honest, clinical information you need — without a sales pitch wrapped around it.

Slinic vs Competitors: Full UK Price Comparison 2026

Before choosing any provider, compare the full picture — not just the headline price. Here is how Slinic’s fixed pricing compares against the major UK weight loss injection providers across every factor that matters. For a detailed independent breakdown see our Top UK Mounjaro Providers comparison guide.

Competitor prices are guide prices verified June 2026 — always confirm directly. Slinic prices are fixed per pen + £4.99 delivery. No subscription, no minimum term.

What Are Weight Loss Injections?

Weight loss injections — more precisely, GLP-1 receptor agonists — are a class of prescription-only medicines originally developed for the management of type 2 diabetes that have since been licensed at higher doses specifically for obesity treatment. They work by mimicking hormones your gut naturally produces after eating, significantly reducing appetite, slowing digestion, and improving blood sugar regulation.

The term “weight loss injection” covers several different medications. The two most important in 2026 are tirzepatide (Mounjaro) and semaglutide (Wegovy). A third option, liraglutide (Saxenda), is available but produces significantly lower average weight loss and is now rarely the appropriate first choice. All three are administered as once-weekly (or in Saxenda’s case, once-daily) subcutaneous injections using pre-filled pens.

These are not appetite suppressants in the older pharmacological sense. They are not stimulants. They do not work through willpower or behaviour change alone — they alter the underlying hormonal signalling that drives hunger and satiety. For patients who have struggled for years with conventional dieting, this mechanism is clinically and psychologically transformative.

How Weight Loss Injections Work: The Mechanism Explained

Understanding why these medications produce such dramatic results requires a brief look at the hormonal systems they act on.

GLP-1 (Glucagon-Like Peptide-1)

GLP-1 is a hormone naturally released by cells in the gut after eating. It performs several important functions: it signals to the brain that you are full, it slows the rate at which the stomach empties its contents (meaning you feel full for longer after eating), and it stimulates the pancreas to release insulin in response to rising blood sugar. When you inject a GLP-1 receptor agonist, you are providing a sustained, amplified version of this natural signal — effectively telling your brain and digestive system that you have eaten when the hunger drive would otherwise be building.

The practical result for most patients is a profound reduction in what many describe as “food noise” — the constant background preoccupation with food, hunger, and eating that characterises obesity and makes conventional dieting so relentlessly difficult. This is not a willpower effect. It is a pharmacological one.

GIP (Glucose-Dependent Insulinotropic Polypeptide)

GIP is a second gut hormone that was previously less well understood in the context of obesity. Mounjaro (tirzepatide) activates both GIP and GLP-1 receptors simultaneously — a dual-action mechanism that no previous weight loss medication achieved. GIP receptor activation appears to enhance the metabolic effects of GLP-1 stimulation, producing greater appetite suppression and greater average weight loss than GLP-1-only medications. This is the pharmacological reason why Mounjaro’s trial results are superior to those of semaglutide at comparable doses.

Beyond weight loss, GLP-1 agonists are also showing significant promise for their anti-inflammatory effects throughout the body — including on joint pain and systemic inflammation. We explore this in our clinical guide to GLP-1 agonists and joint pain.

What Weight Loss Injections Are Available in the UK?

Three weight loss injections are currently licensed by the MHRA for obesity treatment in the UK. Here is a plain-English summary of each:

1. Mounjaro (Tirzepatide) — Dual GIP + GLP-1

The most effective weight loss injection currently available in the UK. Licensed by the MHRA in 2023. Once-weekly injection. Starts at 2.5mg, escalates every four weeks to a maximum of 15mg. Average weight loss of 22.5% of starting body weight at the highest dose in clinical trials. Available at Slinic from £139/month.

2. Wegovy (Semaglutide) — GLP-1 Only

The first obesity-specific GLP-1 agonist to receive NICE approval for NHS use in the UK. Once-weekly injection. Starts at 0.25mg, escalates to a maintenance dose of 2.4mg, with a higher 7.2mg dose available since January 2026. Average weight loss of 14.9% at 2.4mg and 20.7% at 7.2mg. Also has a cardiovascular benefit on its official licence label following the SELECT trial. Available at Slinic from £139/month.

3. Saxenda (Liraglutide) — GLP-1 Only, Daily Injection

An older once-daily GLP-1 injection. NICE-approved under TA664 for NHS tier 3 services. Average weight loss of 5–7% in clinical trials — significantly lower than Mounjaro or Wegovy. Rarely the appropriate first choice in 2026 given the availability of far more effective weekly alternatives. Slinic does not routinely prescribe liraglutide.

Mounjaro (Tirzepatide): A Full Clinical Review

Mounjaro is the most clinically significant development in obesity pharmacotherapy in a generation. Its dual GIP and GLP-1 mechanism produces weight loss results that overlap with bariatric surgery outcomes in a meaningful proportion of trial participants. Understanding the evidence — and the practical realities of treatment — is essential before starting.

The SURMOUNT Trial Programme

Mounjaro’s evidence base comes primarily from the SURMOUNT programme of Phase 3 clinical trials:

• SURMOUNT-1: 2,539 adults with obesity without type 2 diabetes. At the 15mg dose over 72 weeks: average weight loss 22.5%; 91% lost at least 5%; 57% lost at least 20%; 36% lost at least 25%.¹
• SURMOUNT-2: Adults with obesity and type 2 diabetes. Average weight loss 15.7% at 15mg — significant given that metabolic comorbidities typically attenuate GLP-1 response.³
• SURMOUNT-4: Long-term maintenance data showing weight loss is sustained at 88 weeks with continued treatment, and that stopping without established lifestyle habits leads to significant regain within 12 months.⁵
• Head-to-head vs semaglutide (NEJM 2025): Tirzepatide produced statistically significantly greater weight loss than semaglutide 2.4mg across all doses tested.⁴

Slinic Mounjaro Prices 2026 — All Doses

Fixed 2026 prices. Subject to clinician approval before dispatch. Free starter pack (needles + sharps bin) with first order. No subscription. No minimum term. Order Mounjaro at Slinic →

Mounjaro Dosing: Week by Week

The dose escalation schedule is not optional — it is clinically essential for tolerability. Patients who rush through doses experience significantly more gastrointestinal side effects. At Slinic, every dose increase is reviewed and approved at your monthly clinical check-in. For a complete breakdown see our Mounjaro dosing schedule guide.

Who Cannot Take Mounjaro?

Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and must be stopped at least two months before attempting to conceive. Patients with a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy require individual clinical assessment. See our full Mounjaro eligibility guide for complete criteria.

Mounjaro and Thyroid Conditions

For patients on levothyroxine or other thyroid medications, Mounjaro requires additional clinical consideration. Its effect on gastric emptying can alter absorption of thyroid medication, and improving metabolic function through weight loss may affect thyroid function itself. See our Mounjaro and thyroid medication guide for full clinical detail.

Wegovy (Semaglutide): A Full Clinical Review

Wegovy was the first obesity-specific GLP-1 receptor agonist approved for NHS use in the UK and has the longest real-world safety track record of any weekly weight loss injection currently available. The January 2026 approval of the higher 7.2mg dose has significantly narrowed the efficacy gap with Mounjaro, making the choice between them more nuanced than it was 12 months ago.

The STEP Trial Programme

• STEP 1: Average weight loss of 14.9% at the 2.4mg maintenance dose over 68 weeks. 86.4% achieved at least 5% weight loss.⁷
• STEP UP (7.2mg dose): Average weight loss of 20.7% over 72 weeks. Approximately 1 in 3 participants lost 25% or more of starting body weight.²
• SELECT trial: Wegovy is the only weight loss injection with a cardiovascular benefit on its official UK licence label — a 20% reduction in major adverse cardiovascular events in adults with existing heart disease and obesity without diabetes.⁸

The Wegovy 7.2mg Dose

The 7.2mg dose is not a starting dose. It is for patients who have reached and tolerated 2.4mg but have plateaued or need additional results. Currently administered as three consecutive 2.4mg injections on the same day. A dedicated single-injection pen is expected later in 2026. See our complete Wegovy 7.2mg guide.

Slinic Wegovy Prices 2026 — All Doses

Fixed 2026 prices. Subject to clinician approval before dispatch. Free starter pack (needles + sharps bin) with first order. No subscription. No minimum term. Order Wegovy at Slinic →

Wegovy Dosing Schedule

Saxenda (Liraglutide): Still Available, Rarely Best Choice

Saxenda (liraglutide 3mg) is a once-daily GLP-1 injection that remains NICE-approved under TA664 for NHS tier 3 services but produces average weight loss of only 5–7% in clinical trials — considerably lower than Mounjaro or Wegovy.⁹ With Saxenda’s patent expiring in 2025, the branded Novo Nordisk version has had prolonged supply issues and generic versions (Biolide, Nevolat) are now available. Slinic does not routinely prescribe liraglutide given the availability of far superior weekly options, but our clinical team will advise if it is specifically appropriate for your circumstances.

Full Comparison: All Weight Loss Injections UK 2026

Prices correct June 2026. Always verify at slinic.co.uk.

Who Is Eligible for Weight Loss Injections in the UK?

For private prescription through Slinic, eligibility follows the criteria established in clinical guidelines and updated GPhC guidance. See our full eligibility guide for complete detail.

You are likely eligible if you have:

• A BMI of 30 or above, or
• A BMI of 27 or above with at least one weight-related health condition:
  • Type 2 diabetes or pre-diabetes
  • High blood pressure (hypertension)
  • High cholesterol (dyslipidaemia)
  • Obstructive sleep apnoea
  • Cardiovascular disease
  • Non-alcoholic fatty liver disease
• Age 18 or over
• Not pregnant or breastfeeding
• No absolute contraindications identified at clinical assessment

GPhC Independent Weight Verification (February 2025)

Updated GPhC guidance issued in February 2025 requires all online pharmacies to independently verify a patient’s weight, height, and BMI before prescribing weight loss medication. Slinic has complied with this requirement since its introduction. Any provider that does not ask you to verify your weight is not meeting the current regulatory standard — and that is a significant clinical governance concern.

How to Self-Inject: A Step-by-Step Guide

Both Mounjaro and Wegovy come in pre-filled injection pens designed for subcutaneous self-injection. The needle is very fine and the process is considerably less daunting than most patients expect. Here is the general process:

1. Choose your injection site — the abdomen (at least 2 inches from the navel), outer thigh, or upper arm. Rotate sites each week to avoid skin reactions at the same location.
2. Prepare the pen — remove from the fridge and allow to reach room temperature for 30 minutes before injecting. Check the medication is clear and colourless. Check the expiry date.
3. Clean the skin — wipe the injection site with an alcohol swab and allow to dry completely.
4. Inject — remove the cap, press the pen firmly against the skin, and press the button. Hold for the count indicated in the instructions (typically 5–10 seconds) to ensure the full dose is delivered.
5. Dispose safely — place the used pen in your sharps bin. Never place used needles in household waste.

Your Slinic free starter pack includes the pen, needles, a sharps bin, and step-by-step instructions. Your clinician will walk you through the process at your initial video consultation if needed.

Side Effects: What to Expect and How to Manage Them

Both Mounjaro and Wegovy share a similar side effect profile because they both activate GLP-1 receptors. The majority of side effects are gastrointestinal and are most pronounced in the first 4–8 weeks of each new dose. Managing them effectively is one of the key roles of your monthly clinical check-in at Slinic. For a comprehensive patient guide see our Mounjaro side effects guide.

Practical Tips for Managing Side Effects

• Nausea — eat smaller, lower-fat meals; avoid lying down immediately after eating; stay well hydrated; avoid alcohol, especially in the first weeks of each new dose
• Constipation — increase dietary fibre and fluid intake; gentle movement helps; your clinician can advise on suitable laxatives if needed
• Diarrhoea — usually brief and resolves within days; maintain hydration; contact Slinic if persistent
• Hair loss — usually temporary telogen effluvium (stress-related hair shedding) associated with rapid weight loss rather than the medication itself; typically resolves within 3–6 months

Serious but Rare Side Effects

• Pancreatitis — fewer than 0.2% of users. Severe, persistent abdominal pain radiating to the back requires immediate medical attention.
• Gallbladder problems — gallstones in approximately 1–2% of users, more common with rapid weight loss.
• Diabetic retinopathy — patients with existing retinopathy require close monitoring before and during treatment.
• Allergic reactions — rare but require immediate emergency attention.

NHS vs Private Weight Loss Injections in 2026

NHS Access: The Reality in 2026

Mounjaro on the NHS: NICE TA1026 approved tirzepatide for NHS prescribing in 2025. A phased GP rollout began in June 2025, but initial eligibility is tightly restricted — typically BMI 40 or above with at least four weight-related health conditions. This threshold will widen over a 12-year rollout programme, but for most patients with BMI between 30 and 40, NHS Mounjaro is not currently accessible.

Wegovy on the NHS: Available through specialist tier 3 weight management services under NICE TA875, requiring BMI of 35 or above with weight-related conditions. Waiting times in most English ICBs are 12–24 months. The 7.2mg dose has not yet received NICE approval for NHS use.

If you meet NHS eligibility criteria (BMI 35+ with a qualifying condition), I would always encourage you to explore NHS access with your GP first. But if your BMI falls below the NHS threshold, or you cannot wait 12 months or more for a progressive condition, private treatment through a GPhC-regulated provider is the appropriate and safe route.

Cost and Pricing: What You Are Really Paying in 2026

For a complete dose-by-dose breakdown, see our complete Mounjaro cost guide. The key question to ask any provider is not just the headline price — it is what that price actually includes.

All prices verified June 2026. Confirm current pricing directly with each provider.

For an independent comparison of UK providers see our Top UK Mounjaro Providers guide and our guide to safe affordable weight loss injections.

How to Choose a Safe Provider

The MHRA seized 5,851 falsified or unlicensed weight loss injections in 2025 alone — up from just 407 in 2023. The domestic black market for counterfeit GLP-1 medications is real and growing. Choosing a provider should not begin with price — it should begin with regulatory verification.

Seven checks before you commit to any provider:

1. Verify GPhC registration — search pharmacyregulation.org. Slinic’s number is 1033729.
2. Check LegitScript certification — verify Slinic here.
3. Confirm independent weight verification — required under GPhC February 2025 guidance.
4. Ask who reviews your clinical assessment — a registered UK prescriber, not an algorithm.
5. Get the full total price — consultation, needles, sharps bin, delivery all included or itemised.
6. Check subscription terms — understand the cancellation policy before committing.
7. Confirm ongoing clinical support — regular check-ins, not just prescription renewals.

Real-World Results: What UK Patients Actually Achieve

Clinical trial data gives you the best-case benchmark — but real-world outcomes depend on several factors including starting weight, dose reached, diet, activity level, and the quality of clinical support received throughout treatment.

In a real-world UK setting, published research from Second Nature in JMIR Formative Research found participants achieved an average weight loss of 19.1% at 12 months on a semaglutide-supported programme, with 77.7% achieving at least 10% weight loss. This real-world data is consistent with — and in some respects exceeds — the trial findings, because it reflects a clinically supported population rather than a placebo-controlled trial group.

At Slinic, our clinical approach is designed to maximise real-world outcomes. This means starting at the correct dose and escalating carefully, monitoring side effects and adjusting where necessary, and using monthly clinical check-ins to support the dietary and behavioural changes that determine how much weight loss is maintained after treatment ends.

What affects how much weight you lose?

• Starting dose and escalation speed — patients who tolerate escalation to the highest maintenance dose tend to achieve the greatest weight loss. Rushing escalation to manage this leads to side effects and dropout.
• Dietary quality during treatment — medication reduces appetite but does not change food choices. Higher-protein, lower-calorie eating during treatment significantly improves outcomes and reduces hair shedding.
• Activity levels — patients who maintain or increase physical activity during treatment preserve more lean muscle mass and tend to maintain more weight loss after stopping.
• Duration of treatment — weight loss continues to accumulate over 12–18 months at the maintenance dose. Stopping early — before maximum benefit is reached — significantly limits total outcomes.
• Quality of clinical support — patients receiving regular clinical oversight and guidance lose more weight and are more likely to maintain results than those receiving only prescription renewals.

Safety in 2026: What the Latest Data Shows

The 2024 and 2025 MHRA and EMA safety reviews of GLP-1 receptor agonists cleared earlier concerns about mental health effects and thyroid cancer risk at standard licensed doses. The current safety picture for Mounjaro and Wegovy is well-characterised and reassuring for the vast majority of patients when used under appropriate clinical oversight.

Mental health

Concerns about suicidal ideation associated with GLP-1 medications prompted a major EMA review in 2023–2024. The conclusion, based on analysis of clinical trial data and post-marketing surveillance, was that there was no causal link between GLP-1 receptor agonists and suicidal thoughts or behaviour at licensed doses. Some patients report improved mood and mental wellbeing as weight loss progresses — a finding consistent with the established relationship between obesity, inflammation, and mood disorders.

Thyroid safety

Rodent studies showed thyroid C-cell tumours at very high doses of semaglutide and liraglutide. Human studies and post-marketing surveillance have not demonstrated the same signal at licensed clinical doses. Mounjaro and Wegovy remain contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2, and appropriate clinical screening before prescribing is essential.

Cardiovascular safety

Wegovy is the only weight loss injection in the UK with a cardiovascular benefit on its licence label, following the SELECT trial demonstrating a 20% reduction in major cardiovascular events. For Mounjaro, cardiovascular outcome trials are ongoing — early data is positive but a formal cardiovascular benefit label has not yet been approved.

Counterfeit medication risk

The MHRA seized 5,851 falsified or unlicensed weight loss injections in 2025 — a 14-fold increase from 407 in 2023. These counterfeit products cannot be verified for dose, ingredients, or storage compliance, and represent a genuine and growing patient safety risk. Purchasing from a GPhC-registered and LegitScript-certified provider like Slinic is the only way to guarantee you are receiving genuine, properly stored, licensed medication.

Weight Loss Medications Coming Soon

Our guide to retatrutide UK progress and expected availability covers the next generation in full. Here is a brief summary of what is coming:

Retatrutide — Triple GLP-1/GIP/Glucagon Agonist

Eli Lilly’s retatrutide activates three hormone receptors simultaneously. The TRIUMPH-1 Phase 3 trial produced average weight loss of 28.3% at the 12mg dose over 80 weeks — with nearly half of participants at the highest dose losing 30% or more of their body weight.¹⁰ Topline results reported in 2026; not yet peer-reviewed. UK availability most likely 2027–2028 if regulatory submission proceeds as anticipated.

Oral Semaglutide

A once-daily oral form of semaglutide for weight loss launched in the US in January 2026. MHRA review is underway, with a decision expected towards end of 2026. Average weight loss of approximately 13.6% in the OASIS-4 trial. Suitable for patients who prefer a tablet to an injection.

CagriSema and Orforglipron

CagriSema (Novo Nordisk) combines semaglutide with cagrilintide and showed 22.7% average weight loss in the REDEFINE 1 trial. Orforglipron (Eli Lilly’s Foundayo) — a daily oral GLP-1 pill approved by the FDA in April 2026 — showed approximately 12% weight loss. UK availability for both expected 2027 at earliest.

What Happens When You Stop Weight Loss Injections?

This is one of the most important and least discussed aspects of weight loss injection treatment. The clinical evidence is consistent: stopping GLP-1 medication abruptly without having established sustainable dietary and lifestyle habits leads to significant weight regain. Long-term follow-up from SURMOUNT-4 showed that patients who discontinued tirzepatide regained the majority of their lost weight within 12 months without ongoing support.⁵

This does not mean treatment must continue indefinitely — but it does mean that the support and habit formation delivered alongside medication is clinically important, not optional. At Slinic, our monthly clinical check-ins are specifically designed to help you build the lifestyle foundation that will support your weight long after treatment ends.

If you need to restart treatment after a break, see our guide to restarting Mounjaro safely.

Frequently Asked Questions

Clinical References

1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022;387(3):205-216.
2. Wharton S, et al. Once-weekly semaglutide 7.2mg (STEP UP). Lancet Diabetes & Endocrinology. 2025;13(11):949-963.
3. Garvey WT, et al. Tirzepatide for obesity in type 2 diabetes (SURMOUNT-2). The Lancet. 2023;402:613-626.
4. Aronne LJ, et al. Tirzepatide vs Semaglutide for Obesity. NEJM. 2025;393(1):26-36.
5. Aronne LJ, et al. Continued Treatment With Tirzepatide (SURMOUNT-4). JAMA. 2024;331(1):38-48.
6. MHRA Drug Safety Update: Tirzepatide (Mounjaro). January 2025.
7. Wilding JPH, et al. Once-Weekly Semaglutide (STEP 1). NEJM. 2021;384(11):989-1002.
8. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes (SELECT). NEJM. 2023;389(24):2221-2232.
9. Pi-Sunyer X, et al. Liraglutide 3mg in Weight Management (SCALE). NEJM. 2015;373(1):11-22.
10. Eli Lilly. TRIUMPH-1 topline results. 2026. Not yet peer-reviewed.
11. NICE TA1026 — Tirzepatide for overweight and obesity.
12. NICE TA875 — Semaglutide for overweight and obesity.
13. GPhC guidance for online pharmacies — updated February 2025. pharmacyregulation.org

Related Guides & Treatment Pages